Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT).

The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or metastatic UC previously treated with ...

Based on work Dr. Petrylak presented at ASCO 2024 looking at dose adjustment and efficacy of enfortumab vedotin, most ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Dr. Micheal Ge, CEO of Kelun-Biotech said, "It is a great pleasure to share with you the important milestone moment of the successful approval and launch of sacituzumab tirumotecan in China, which is ...

of its anti-TROP2 ADC sacituzumab tirumotecan (sac-TMT, formerly SKB-264/MK-2870) as monotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (UC) who progressed ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.